Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors

OBJECTIVE: To evaluate effects of the anti-interleukin-6 receptor monoclonal antibody sarilumab administered with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on patient-reported outcomes (PROs) in the TARGET trial in patients with rheumatoid arthritis (RA) with inadequate...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:RMD Open
Auteurs principaux: Strand, Vibeke, Reaney, Matthew, Chen, Chieh-I, Proudfoot, Clare W J, Guillonneau, Sophie, Bauer, Deborah, Mangan, Erin, Graham, Neil M H, van Hoogstraten, Hubert, Lin, Yong, Pacheco-Tena, César, Fleischmann, Roy
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2017
Sujets:
Rheumatoid Arthritis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5353328/
https://ncbi.nlm.nih.gov/pubmed/28326189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000416
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires